Wockhardt
 | |
 Wockhardt global headquarters in Mumbai | |
| Type | Public |
|---|---|
| NSE: WOCKPHARMA BSE: 532300 | |
| Industry | Pharmaceuticals Health care |
| Founded | 1960s |
| Founder | Habil Khorakiwala |
| Headquarters | Wockhardt Towers, Bandra Kurla Complex, Mumbai, Maharashtra, India |
Area served | Worldwide |
| Key people | Habil Khorakiwala (Chairman) Murtaza Khorakiwala (Managing director) Huzaifa Khorakiwala (Executive Director) |
| Products | Formulations Biopharmaceuticals Vaccines |
| Revenue |  ₹2,693 crore (US$280 million) (FY23) |
 ₹−621 crore (US$−64 million) (FY23) | |
Number of employees | 3,000 (2023) |
| Subsidiaries | Morton Grove Pharma |
| Website | www |
| Footnotes | |
Wockhardt is an Indian pharmaceutical and biotechnology company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company has manufacturing plants in India, the UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.